The final late-breaking abstract deadline of 7 August 2024 isunder no circumstancesto be considered as an extension of the general submission deadline. Trial in progress abstracts (TiP)-进行中的试验摘要 Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) ma...
The final late-breaking abstract deadline of 7 August 2024 isunder no circumstancesto be considered as an extension of the general submission deadline. Trial in progress abstracts (TiP)-进行中的试验摘要 Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) ma...
We look forward to welcoming you again to Lugano in 2024, to share with you the latest original scientific data in these rare sub-entities. Scientific Co-Chairs Jean-Yves Blay, Lyon, France Robin Jones, London, UK Claudia Valverde Morales, Barcelona, Spain 摘要征文投稿: Abstract submission de...
ESMO membership must be active seven (7) days prior to the registration deadline for the reduced member registration fee to be applied.Please visit themembership pageto check eligibility criteria, benefits, and to complete the membership application. * Applicable to ESMO Members from developing count...
Recruitment must have already begun or have been completed by the abstract submission deadline of 21 February 2023. Abstracts including results or preliminary data will be rejected. Trial in Progress abstracts will be accepted for Poster outcome only. ...
提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations Submission categories Central Nervous System (CNS) Digestive cancers Genitourinary cancers Gynaecological cancers Head and neck cancers Neuroendocrine and Endocrine cancers Public Policy and Patient Advocacy ...
The final late-breaking abstract deadline of 17 April 2024 is under no circumstances to be considered as an extension of the general submission deadline (13 February 2024). Trial in Progress abstracts Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III)...
Only abstracts for whichno conclusive data are available at the time of the abstract submission deadline of9 January 2024will be considered for late-breaking status. The workmust nothave been previously published in any publication in a peer review setting or presented at a meeting of any other...
Only abstracts for whichno conclusive data are available at the time of the abstract submission deadline of9 January 2024will be considered for late-breaking status. The workmust nothave been previously published in any publication in a peer review setting or presented at a meeting of any other...
Abstract submission deadline 点此提交摘要>>>Submit Abstract>>> ESMO TAT 2024 Abstract Regulations>>>提交指南 Abstract submission categories Antibody-based therapies Cellular and gene therapies DNA damage repair and epigenetics Immunotherapy Kinase-targeting agents and cell signalling modulators ...